Table 1.

Basic demographics and disease characteristics

	ALE	RRMS	IDH-WT glioma	CNS-DLBCL	SD	HC
Number of patients	81	168	51	9	110	19
Basic mFC analysis (PB & CSF)	81	148	33	9	110	0
In-depth mFC analysis (PBMCs)	0	20	18	0	0	19
Age (median with range) [years]	57 [17–80]	31 [15–61]	61 [20–86]	71 [61–90]	36 [15–79]	54 [45–69]
Sex [% female]	43.21	71.43	37.25	22.22	69.09	36.84
AABs [%]	Intra: 23.46 Extra: 24.69 Unknown: 2.47 AAB−: 49.38	NA	NA	NA	NA	NA
Immunotherapy within 4 weeks prior to sampling [%]	PLEX: 1.23 Steroids: 17.28	None	Steroids: 17.65	None	None	None

AAB⁻ autoantibody-negative, AABs autoantibodies, ALE autoimmune limbic encephalitis, CSF cerebrospinal fluid, CNS-DLBCL diffuse large B cell lymphoma of the central nervous system, Extra extracellular target epitope, HC healthy control, IDH isocitrate dehydrogenase, Intra intracellular target epitope, mFC multidimensional flow cytometry, NA not available, PB peripheral blood, PBMCs peripheral blood mononuclear cells, PLEX plasmapheresis, RRMS relapsing–remitting multiple sclerosis, SD somatic symptom disorder, WT wildtype